Muhlis Akman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Muhlis Akman has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Riganti
Department of Oncology, University of Torino, 10126 Torino, Italy
109 shared publications - Iris Chiara Salaroglio
Department of Oncology, University of Torino, Torino, Italy
107 shared publications - Dario Pasquale Anobile
Department of Oncology University of Torino, Italy
106 shared publications - Joanna Kopecka
Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy
106 shared publications - Elisabetta Aldieri
Department of Oncology, University of Torino, 10126 Torino, Italy
105 shared publications - Fabrizio Tabbò
Ospedale Michele e Pietro Ferrero, Cuneo, Italy
105 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 382
Interleukin-1 receptor-associated kinase 1 controls chemoresistance and immuno-killing in non-small cell lung cancer
- 15 September 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 382
Open AccessInterleukin-1 receptor-associated kinase 1 controls chemoresistance and immuno-killing in non-small cell lung cancer
- Open Access
- 2 August 2026
- Published by Elsevier in Drug Resistance Updates
- Vol. 89
Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance
- 2 August 2026
- Published by Elsevier in Drug Resistance Updates
- Vol. 89
Open AccessTargeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance
- Open Access
- 21 April 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 50 (2) , 170-184
Combinatorial effect of epirubicin and 5-fluorouracil in the treatment of temozolomide-resistant glioblastoma cells
Background: Glioblastoma (GBM) is a highly aggressive form of brain tumor characterized by rapid proliferation and invasiveness. It is associated with a poor prognosis due to acquired resistance to temozolomide (TMZ). In this study, we investigated whether a combination of epirubicin, 5-fluorouracil (5-FU), and TMZ could improve TMZ sensitivity in resistant GBM cells and help overcome resistance.Materials and methods: TMZ resistance was established in the U87MG cell line. The MTT assay was used to measure cell viability. Reactive oxygen species (ROS) and apoptosis were measured using flow cytometry. RNA-seq was used to evaluate genomic changes based on treatment with drugs alone or in combination. Results: We demonstrated that the triple-drug combination significantly reduced cell viability. The biochemical pathways involved revealed that this combination therapy significantly increased the generation of ROS. The RNA-seq analysis indicated that combination therapy effectively suppressed cell cycle regulatory pathways, enhancing cell cycle arrest and promoting apoptosis in TMZ-resistant cells. Conclusion: These findings underscore the potential viability of integrating epirubicin and 5-FU with TMZ to improve therapeutic outcomes in patients suffering from chemoresistant GBM. These combination therapies could represent an important advance in the treatment of this challenging malignancy.
- 21 April 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 50 (2) , 170-184
Open AccessCombinatorial effect of epirubicin and 5-fluorouracil in the treatment of temozolomide-resistant glioblastoma cells
Background: Glioblastoma (GBM) is a highly aggressive form of brain tumor characterized by rapid proliferation and invasiveness. It is associated with a poor prognosis due to acquired resistance to temozolomide (TMZ). In this study, we investigated whether a combination of epirubicin, 5-fluorouracil (5-FU), and TMZ could improve TMZ sensitivity in resistant GBM cells and help overcome resistance.Materials and methods: TMZ resistance was established in the U87MG cell line. The MTT assay was used to measure cell viability. Reactive oxygen species (ROS) and apoptosis were measured using flow cytometry. RNA-seq was used to evaluate genomic changes based on treatment with drugs alone or in combination. Results: We demonstrated that the triple-drug combination significantly reduced cell viability. The biochemical pathways involved revealed that this combination therapy significantly increased the generation of ROS. The RNA-seq analysis indicated that combination therapy effectively suppressed cell cycle regulatory pathways, enhancing cell cycle arrest and promoting apoptosis in TMZ-resistant cells. Conclusion: These findings underscore the potential viability of integrating epirubicin and 5-FU with TMZ to improve therapeutic outcomes in patients suffering from chemoresistant GBM. These combination therapies could represent an important advance in the treatment of this challenging malignancy.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Outcome of non-small cell lung cancer patients in LUAD TCGA cohort. a. OS of patients of lung adenocarcinoma (LUAD) dataset of The Cancer Genome Atlas (TCGA), stratified according to the gender. F: females; M: males. b-c. OS of LUAD TCGA female and male patients, stratified according to the median expression value of CD274/PD-L1 mRNA. d-e. OS of LUAD TCGA female and male patients, stratified according to the median expression value of ESR1/ERα mRNA. f-g. OS of LUAD TCGA female and male patients, stratified according to the co-expression phenotypes: CD274high/ESR1high, CD274high/ESR1low, CD274low/ESR1high, CD274low/ESR1low. P:0.005 for CD274high/ESR1high versus CD274low/ESR1low group. h. Expression of ERα mRNA, plotted versus PD-L1 mRNA, both measured by RT-PCR (technical triplicates) in the tumor samples from F and M patients.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Outcome of non-small cell lung cancer patients in LUAD TCGA cohort. a. OS of patients of lung adenocarcinoma (LUAD) dataset of The Cancer Genome Atlas (TCGA), stratified according to the gender. F: females; M: males. b-c. OS of LUAD TCGA female and male patients, stratified according to the median expression value of CD274/PD-L1 mRNA. d-e. OS of LUAD TCGA female and male patients, stratified according to the median expression value of ESR1/ERα mRNA. f-g. OS of LUAD TCGA female and male patients, stratified according to the co-expression phenotypes: CD274high/ESR1high, CD274high/ESR1low, CD274low/ESR1high, CD274low/ESR1low. P:0.005 for CD274high/ESR1high versus CD274low/ESR1low group. h. Expression of ERα mRNA, plotted versus PD-L1 mRNA, both measured by RT-PCR (technical triplicates) in the tumor samples from F and M patients.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Activity of ERβ on CD274/PD-L1 promoter. Chromatin immunoprecipitation of ERE1 and ERE2 regions from CD274/PD-L1 promoter, using an anti-ERα or an anti-ERβ antibody, followed by RT-PCR (technical triplicates) of the precipitated products, in ERα highNCI-H1975 cells, grown 24 h in fresh medium (Ctrl) or in medium containing 10 nM fluvestrant (Fulv), an ERα inhibitor, or 10 nM letrozole (Letr), an aromatase inhibitor. Data are means+SD (n=3). **p<0.01, ***p<0.001: treated cells versus Ctrl cells; °°°p<0.001: anti-ERβ versus anti-ERα.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Activity of ERβ on CD274/PD-L1 promoter. Chromatin immunoprecipitation of ERE1 and ERE2 regions from CD274/PD-L1 promoter, using an anti-ERα or an anti-ERβ antibody, followed by RT-PCR (technical triplicates) of the precipitated products, in ERα highNCI-H1975 cells, grown 24 h in fresh medium (Ctrl) or in medium containing 10 nM fluvestrant (Fulv), an ERα inhibitor, or 10 nM letrozole (Letr), an aromatase inhibitor. Data are means+SD (n=3). **p<0.01, ***p<0.001: treated cells versus Ctrl cells; °°°p<0.001: anti-ERβ versus anti-ERα.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Levels of progesterone, testosterone and respective receptors in non-small cell lung cancer cells a-b. Levels of progesterone (panel a) and testosterone (panel b), measured by ELISA (technical triplicates), in female (F)-derived NCI-H1385 and NCI-H1975 cells, and in male (M)-derived A549 and NCI-H1650 cells. Data are means+SD (n=3, biological replicates). °p<0.05: M-derived cells versus mean of F-derived cells (ANOVA). c-d. Progesterone receptor (PR; panel c) and androgen receptor (AR; panel d) mRNA, measured by RT-PCR (technical triplicates). The relative expression of each gene in NCI-H1385 cells was considered 1. Data are means + SD (n=3, biological replicates). ***p<0.001: NCI-H1975 cells versus NCI-H1385; °°p<0.01: M-derived cells versus mean of F-derived cells (ANOVA). e. Immunoblot of the indicated proteins in nuclear extracts. TBP is included as control of equal protein loading. The image is representative of one of three experiments.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Levels of progesterone, testosterone and respective receptors in non-small cell lung cancer cells a-b. Levels of progesterone (panel a) and testosterone (panel b), measured by ELISA (technical triplicates), in female (F)-derived NCI-H1385 and NCI-H1975 cells, and in male (M)-derived A549 and NCI-H1650 cells. Data are means+SD (n=3, biological replicates). °p<0.05: M-derived cells versus mean of F-derived cells (ANOVA). c-d. Progesterone receptor (PR; panel c) and androgen receptor (AR; panel d) mRNA, measured by RT-PCR (technical triplicates). The relative expression of each gene in NCI-H1385 cells was considered 1. Data are means + SD (n=3, biological replicates). ***p<0.001: NCI-H1975 cells versus NCI-H1385; °°p<0.01: M-derived cells versus mean of F-derived cells (ANOVA). e. Immunoblot of the indicated proteins in nuclear extracts. TBP is included as control of equal protein loading. The image is representative of one of three experiments.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Levels of ERβ and ERα target genes in non-small cell lung cancer cells a. ERβ mRNA, measured by RT-PCR (technical triplicates), in female (F)-derived NCI-H1385 and NCI-H1975 cells, and in male (M)-derived A549 and NCI-H1650 cells. The relative expression of ERβ in NCI-H1385 cells was considered 1. Data are means+SD (n=3). ***p<0.001: NCI-H1975 cells versus NCI-H1385; °°p<0.01: M-derived cells versus mean of F-derived cells (ANOVA). b. Expression of ERβ mRNA, measured by RT-PCR (technical triplicates), plotted versus expression of surface PD-L1, measured by flow cytometry (technical triplicates), in 29 human NSCLC cell lines derived from F or M patients. c. Expression of ERα-target genes CXCL12, IGFBP4 and ABCA3, measured by RT-PCR (technical triplicates). The relative expression of each gene in NCI-H1385 cells was considered 1. Data are means+SD (n=3). *p<0.05, ***p<0.001: NCI-H1975 cells versus NCI-H1385; °p<0.05, °°p<0.01, °°°p<0.001: M-derived cells versus mean of F-derived cells (ANOVA).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Levels of ERβ and ERα target genes in non-small cell lung cancer cells a. ERβ mRNA, measured by RT-PCR (technical triplicates), in female (F)-derived NCI-H1385 and NCI-H1975 cells, and in male (M)-derived A549 and NCI-H1650 cells. The relative expression of ERβ in NCI-H1385 cells was considered 1. Data are means+SD (n=3). ***p<0.001: NCI-H1975 cells versus NCI-H1385; °°p<0.01: M-derived cells versus mean of F-derived cells (ANOVA). b. Expression of ERβ mRNA, measured by RT-PCR (technical triplicates), plotted versus expression of surface PD-L1, measured by flow cytometry (technical triplicates), in 29 human NSCLC cell lines derived from F or M patients. c. Expression of ERα-target genes CXCL12, IGFBP4 and ABCA3, measured by RT-PCR (technical triplicates). The relative expression of each gene in NCI-H1385 cells was considered 1. Data are means+SD (n=3). *p<0.05, ***p<0.001: NCI-H1975 cells versus NCI-H1385; °p<0.05, °°p<0.01, °°°p<0.001: M-derived cells versus mean of F-derived cells (ANOVA).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Switch-off/on EGFR activity in NCI-H1385 cells. a. Experimental scheme: Low EGFR activitywild-type NCI-H1385 cells were knocked-out (KO) for endogenous EGFR by a CRISPR/Cas vector, then stably transfected with an expression vector encoding L858R EGFR. b. Immunoblot of EGFR in wild-type (wt) NCI-H1385 cells and in clones subjected to two (#1, #2) EGFR-CRISPR/Cas vectors. Tubulin is included as control of equal protein loading. The image is representative of one of three experiments. c. L858R EGFR mRNA levels in wt NCI-H1385 cells and in cells stably transfected with the L858R EGFR-expression vector, measured by RT-PCR (technical triplicates). Data are means + SD (n=3, biological replicates). ***p<0.001: L858R cells versus wt cells (ANOVA). d. Immunoblot of EGFR in wt and L858R NCI-H1385 cells. Tubulin is included as control of equal protein loading. The image is representative of one of three experiments. e. EGFR kinase activity, measured in wt and L858R NCI-H1385 cells by a chemiluminescence-based assay in technical duplicates. Data are means+SD (n=3, biological replicates). ***p<0.001: L858R cells versus wt cells (ANOVA).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Switch-off/on EGFR activity in NCI-H1385 cells. a. Experimental scheme: Low EGFR activitywild-type NCI-H1385 cells were knocked-out (KO) for endogenous EGFR by a CRISPR/Cas vector, then stably transfected with an expression vector encoding L858R EGFR. b. Immunoblot of EGFR in wild-type (wt) NCI-H1385 cells and in clones subjected to two (#1, #2) EGFR-CRISPR/Cas vectors. Tubulin is included as control of equal protein loading. The image is representative of one of three experiments. c. L858R EGFR mRNA levels in wt NCI-H1385 cells and in cells stably transfected with the L858R EGFR-expression vector, measured by RT-PCR (technical triplicates). Data are means + SD (n=3, biological replicates). ***p<0.001: L858R cells versus wt cells (ANOVA). d. Immunoblot of EGFR in wt and L858R NCI-H1385 cells. Tubulin is included as control of equal protein loading. The image is representative of one of three experiments. e. EGFR kinase activity, measured in wt and L858R NCI-H1385 cells by a chemiluminescence-based assay in technical duplicates. Data are means+SD (n=3, biological replicates). ***p<0.001: L858R cells versus wt cells (ANOVA).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Levels of FSHR and LHR in non-small cell lung cancer cells FSHR (panel a) and LHR (panel b) mRNA, measured by RT-PCR (technical triplicates), in female (F)-derived NCI-H1385 and NCI-H1975 cells, and in male (M)-derived A549 and NCI-H1650 cells. The relative expression of each gene in NCI-H1385 cells was considered 1. Data are means+SD (n=3, biological replicates).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Levels of FSHR and LHR in non-small cell lung cancer cells FSHR (panel a) and LHR (panel b) mRNA, measured by RT-PCR (technical triplicates), in female (F)-derived NCI-H1385 and NCI-H1975 cells, and in male (M)-derived A549 and NCI-H1650 cells. The relative expression of each gene in NCI-H1385 cells was considered 1. Data are means+SD (n=3, biological replicates).